Today, the US Supreme Court is scheduled to hear oral arguments in a legal challenge of an Arkansas law that regulates the reimbursement rates that pharmacy benefit managers (PBMs) pay to pharmacies.
Author Archive for: sarah-lanford
About Sarah Lanford
Sarah Lanford joined NASHP in August 2018. As a policy associate, she works with the Emerging Policy Issues team, and projects related to prescription drug costs. Before joining NASHP, Sarah worked at Stateside Associates, where she monitored and analyzed state health policy legislation. She has also worked for the Texas Democratic Party and the Texas State Senate, and served as a page in the United States Senate. She holds a BA in government from the University of Texas at Austin.
Entries by Sarah Lanford
At least 11 states have acted to limit the dispensing of chloroquine and hydroxychloroquine – prescription drugs that have been cited as providing protection against coronavirus (COVID-19) without adequate clinical evidence to support that claim. To protect consumers with or at risk of COVID-19 and to prevent stockpiling of these drugs, which treat malaria, rheumatoid […]
In their 2020 state of the state speeches, governors identified new health policy initiatives on a wide range of issues. As of mid-February, 42 governors had delivered speeches or outlined key budget priorities, and all addressed health issues – most commonly strategies to tackle health care costs and behavioral health issues. Below are highlights of the key health themes […]
Last week, California enacted the first-in-the-nation state law to combat pay-for-delay deals between brand-name and generic pharmaceutical drug manufacturers. In a pay-for-delay deal, a brand manufacturer pays a generic competitor to settle patent litigation and keep the lower-cost version of the drug off the market. Delaying market entry of generic drugs limits competition and can […]
To address America’s drug pricing problem, state policymakers face myriad conflicts and trade-offs, inadequate information about the “black box” of drug pricing, and an uncertain road map for how best to address the issue. This NASHP guest report, published in the September 2019 edition of the Journal of Legal Medicine, provides an overview of challenges states face […]
In 2019, states built on the momentum that had been gaining in recent years and passed targeted legislation to address the role harmful pharmacy benefit manager (PBM) business practices play in escalating prescription drug prices. The laws supporting these approaches, described below, give states enforcement mechanisms to ensure that the discounts that PBMs recoup are […]